Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
Ciara M. Kelly, Cristina R. Antonescu, Timothy G. Bowler, et al.
JAMA Oncology (2020) Vol. 6, Iss. 3, pp. 402-402
Open Access | Times Cited: 156

Showing 1-25 of 156 citing articles:

Targeting the gut and tumor microbiota in cancer
Elizabeth M. Park, Manoj Chelvanambi, Neal Bhutiani, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 690-703
Closed Access | Times Cited: 320
Treatment of Advanced Melanoma in 2020 and Beyond
Russell W. Jenkins, David E. Fisher
Journal of Investigative Dermatology (2020) Vol. 141, Iss. 1, pp. 23-31
Open Access | Times Cited: 279
Oncolytic viruses for cancer immunotherapy
Otto Hemminki, João M. Santos, Akseli Hemminki
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 257
Current approaches of nanomedicines in the market and various stage of clinical translation
Xiaoting Shan, Xiang Gong, Jie Li, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 7, pp. 3028-3048
Open Access | Times Cited: 208
Viral vector‐based gene therapies in the clinic
Zongmin Zhao, Aaron C. Anselmo, Samir Mitragotri
Bioengineering & Translational Medicine (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 182
Oncolytic virotherapy: basic principles, recent advances and future directions
Danni Lin, Yinan Shen, Tingbo Liang
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 163
Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 162
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 135
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J. Wagner, Megan Othus, Sandip Pravin Patel, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002990-e002990
Open Access | Times Cited: 110
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Yangfu Jiang, Hongying Zhang, Jiao Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 72
A Dual‐Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis
Wen Su, Wei Qiu, Shu‐Jin Li, et al.
Advanced Materials (2022) Vol. 35, Iss. 11
Closed Access | Times Cited: 69
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma
Seth M. Pollack, Mary W. Redman, Kelsey K. Baker, et al.
JAMA Oncology (2020) Vol. 6, Iss. 11, pp. 1778-1778
Open Access | Times Cited: 100
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis
Michael Saerens, Nele Brusselaers, Sylvie Rottey, et al.
European Journal of Cancer (2021) Vol. 152, pp. 165-182
Open Access | Times Cited: 86
Clinical Application of Oncolytic Viruses: A Systematic Review
Mary A. Cook, Aman Chauhan
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 20, pp. 7505-7505
Open Access | Times Cited: 79
Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
Bharat Burman, Giulio Pesci, Dmitriy Zamarin
Cancers (2020) Vol. 12, Iss. 12, pp. 3552-3552
Open Access | Times Cited: 77
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
Sean J. Judge, Morgan Darrow, Steve W Thorpe, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001355-e001355
Open Access | Times Cited: 75
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Kjetil Boye, Alessandra Longhi, Tormod K. Guren, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 9, pp. 2617-2624
Open Access | Times Cited: 73
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
Matthieu Roulleaux Dugage, Elise F. Nassif, Antoîne Italiano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 60
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Harsimrat Kaur Birdi, Anna Jirovec, Serena Cortés-Kaplan, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 2, pp. e001580-e001580
Open Access | Times Cited: 59
Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy
Weiyue Ban, Jianhuan Guan, Hanwei Huang, et al.
Nano Research (2022) Vol. 15, Iss. 5, pp. 4137-4153
Open Access | Times Cited: 56
Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
Howard L. Kaufman, Sophia Z. Shalhout, Gail Iodice
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 50
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements
Chae‐Ok Yun, JinWoo Hong, A‐Rum Yoon
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 40
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Ciara M. Kelly, Li‐Xuan Qin, Karissa Whiting, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 11, pp. 2043-2051
Open Access | Times Cited: 36
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide
Maud Toulmonde, Jean‐Philippe Guégan, Mariella Spalato Ceruso, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top